Elize Massard da Fonseca

Elize Massard da Fonseca

Auto-generated profile, based on publicly available information

Elize Massard da Fonseca

Sao Paulo School of Business Administration, Getulio Vargas Foundation , Sao Paulo

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2020 in Global Public Health
Verified
Journal Article
Closed access
SGScott L. Greer
Scott L. Greer
Elizabeth J. KingElizabeth J. King
Elizabeth J. King
EFElize Massard da Fonseca
Elize Massard da Fonseca
APAndre Peralta-Santos
Andre Peralta-Santos
COVID-19 has created a ramifying public health, economic, and political crisis throughout many countries in the world. While globally the pandemic is at different stages and far from under control in some countries, now is the time for public health researchers and political scientists to start understanding how and why governments responded the way they have, explore how effective these responses appear to be, and what lessons we can draw about effective public health policymaking in preparation of the next wave of COVID-19 or the next infectious disease pandemic. We argue that there will be no way to understand the different responses to COVID-19 and their effects without understanding policy and politics. We propose four key focuses to understand the reasons for COVID-19 responses: social policies to crisis management as well as recovery, regime type (democracy or autocracy), formal political institutions (federalism, presidentialism), and state capacity (control over health care systems and public administration). A research agenda to address the COVID-19 pandemic that takes politics as a serious focus can enable the development of more realistic, sustainable interventions in policies and shape our broader understanding of the politics of public health.

1 January 2021
Verified
Book
Open access
SGScott Greer
Scott Greer
Elizabeth J. KingElizabeth J. King
Elizabeth J. King
EFElize Fonseca
Elize Fonseca
APAndré Peralta-Santos
André Peralta-Santos
COVID-19 is probably the most significant global crisis of any of our lifetimes. The numbers involved have been stupefying, whether they speak of infection and mortality, the scale of public health measures such as mobility restrictions, or the economic consequences for unemployment and public...

13 November 2007 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
ANAmy S Nunn
Amy S Nunn
EFElize M Fonseca
Elize M Fonseca
FBFrancisco I Bastos
Francisco I Bastos
SGSofia Gruskin
Sofia Gruskin
JSJoshua A Salomon
Joshua A Salomon
Little is known about the long-term drug costs associated with treating AIDS in developing countries. Brazil's AIDS treatment program has been cited widely as the developing world's largest and most successful AIDS treatment program. The program guarantees free access to highly active antiretroviral therapy (HAART) for all people living with HIV/AIDS in need of treatment. Brazil produces non-patented generic antiretroviral drugs (ARVs), procures many patented ARVs with negotiated price reductions, and recently issued a compulsory license to import one patented ARV. In this study, we investigate the drivers of recent ARV cost trends in Brazil through analysis of drug-specific prices and expenditures between 2001 and 2005. We compared Brazil's ARV prices to those in other low- and middle-income countries. We analyzed trends in drug expenditures for HAART in Brazil from 2001 to 2005 on the basis of cost data disaggregated by each ARV purchased by the Brazilian program. We decomposed the overall changes in expenditures to compare the relative impacts of changes in drug prices and drug purchase quantities. We also estimated the excess costs attributable to the difference between prices for generics in Brazil and the lowest global prices for these drugs. Finally, we estimated the savings attributable to Brazil's reduced prices for patented drugs. Negotiated drug prices in Brazil are lowest for patented ARVs for which generic competition is emerging. In recent years, the prices for efavirenz and lopinavir–ritonavir (lopinavir/r) have been lower in Brazil than in other middle-income countries. In contrast, the price of tenofovir is US$200 higher per patient per year than that reported in other middle-income countries. Despite precipitous price declines for four patented ARVs, total Brazilian drug expenditures doubled, to reach US$414 million in 2005. We find that the major driver of cost increases was increased purchase quantities of six specific drugs: patented lopinavir/r, efavirenz, tenofovir, atazanavir, enfuvirtide, and a locally produced generic, fixed-dose combination of zidovudine and lamivudine (AZT/3TC). Because prices declined for many of the patented drugs that constitute the largest share of drug costs, nearly the entire increase in overall drug expenditures between 2001 and 2005 is attributable to increases in drug quantities. Had all drug quantities been held constant from 2001 until 2005 (or for those drugs entering treatment guidelines after 2001, held constant between the year of introduction and 2005), total costs would have increased by only an estimated US$7 million. We estimate that in the absence of price declines for patented drugs, Brazil would have spent a cumulative total of US$2 billion on drugs for HAART between 2001 and 2005, implying a savings of US$1.2 billion from price declines. Finally, in comparing Brazilian prices for locally produced generic ARVs to the lowest international prices meeting global pharmaceutical quality standards, we find that current prices for Brazil's locally produced generics are generally much higher than corresponding global prices, and note that these prices have risen in Brazil while declining globally. We estimate the excess costs of Brazil's locally produced generics totaled US$110 million from 2001 to 2005. Despite Brazil's more costly generic ARVs, the net result of ARV price changes has been a cost savings of approximately US$1 billion since 2001. HAART costs have nevertheless risen steeply as Brazil has scaled up treatment. These trends may foreshadow future AIDS treatment cost trends in other developing countries as more people start treatment, AIDS patients live longer and move from first-line to second and third-line treatment, AIDS treatment becomes more complex, generic competition emerges, and newer patented drugs become available. The specific application of the Brazilian model to other countries will depend, however, on the strength of their health systems, intellectual property regulations, epidemiological profiles, AIDS treatment guidelines, and differing capacities to produce drugs locally.

23 June 2021 in Global Public Health
Verified
Journal Article
Closed access
EFElize Massard da Fonseca
Elize Massard da Fonseca
NNNicoli Nattrass
Nicoli Nattrass
Lira Luz Benites LazaroLira Luz Benites Lazaro
Lira Luz Benites Lazaro
FBFrancisco Inácio Bastos
Francisco Inácio Bastos
The COVID-19 pandemic posed challenges for healthcare systems and political leaders across the globe. In this case study of Brazil, we argue that leadership failings at the highest level contributed to Brazil’s relatively high and escalating death rates during 2020. Drawing on an analysis of a large amount of textual documentation drawn from media reports, we emphasise the role and consequences of President Jair Bolsonaro’s political discourse and prioritisation of the economy. We focus on the first wave that swept across the globe between January and late June of 2020, arguing that Bolsonaro underplayed the seriousness of the epidemic, leveraged misinformation as a political strategy, promoted pseudoscience, and undermined the Ministry of Health. He also confronted subnational governments for adopting lockdown measures – a move that enabled him to blame regional governors for the short-term economic costs of COVID-19 related restrictions. We suggest that his denialist approach to climate change paved the way for his subsequent denialism of the seriousness of COVID-19 and for his undermining of social distancing, mask-wearing and other preventative responses supported by science. These sobering findings highlight the role that national leaders can play in undermining scientific approaches to both public health and the environment.

2 June 2021 in Social Science & Medicine
Verified
Journal Article
Closed access
EFElize Massard da Fonseca
Elize Massard da Fonseca
KSKenneth C. Shadlen
Kenneth C. Shadlen
FBFrancisco I. Bastos
Francisco I. Bastos

1 July 2009 in Health Affairs
Verified
Journal Article
Closed access
ANAmy Stewart Nunn
Amy Stewart Nunn
EFElize Massard da Fonseca
Elize Massard da Fonseca
FBFrancisco I. Bastos
Francisco I. Bastos
SGSofia Gruskin
Sofia Gruskin
Brazil has one of the developing world’s largest, and arguably most successful, AIDS treatment programs. In this paper we review the treatment program, including controversial policies that Brazil has used to promote widespread local and global access to AIDS treatment. We also examine the lessons learned from this program and highlight the challenges Brazil faces, including the rising costs of AIDS treatment and changes in donors’ funding priorities. Finally, we explore the relevance of Brazil’s treatment program for other countries and its broad implications for global AIDS and health policy.